N-ethyl-6-(4-(4-fluorophenyl)oxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-amine

ID: ALA213451

Chembl Id: CHEMBL213451

PubChem CID: 23647330

Max Phase: Preclinical

Molecular Formula: C17H14FN5O

Molecular Weight: 323.33

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCNc1nnc2ccc(-c3ocnc3-c3ccc(F)cc3)cn12

Standard InChI:  InChI=1S/C17H14FN5O/c1-2-19-17-22-21-14-8-5-12(9-23(14)17)16-15(20-10-24-16)11-3-6-13(18)7-4-11/h3-10H,2H2,1H3,(H,19,22)

Standard InChI Key:  IWELIULLJBIPIQ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA213451

   Triazolopyridine oxazole inhibitor 43

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 323.33

Molecular Weight (Monoisotopic): 323.1182

AlogP: 3.62

#Rotatable Bonds: 4

Polar Surface Area: 68.25

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 2.68

CX LogP: 2.00

CX LogD: 2.00

Aromatic Rings: 4

Heavy Atoms: 24

QED Weighted: 0.62

Np Likeness Score: -1.52

References

1. McClure KF, Letavic MA, Kalgutkar AS, Gabel CA, Audoly L, Barberia JT, Braganza JF, Carter D, Carty TJ, Cortina SR, Dombroski MA, Donahue KM, Elliott NC, Gibbons CP, Jordan CK, Kuperman AV, Labasi JM, Laliberte RE, McCoy JM, Naiman BM, Nelson KL, Nguyen HT, Peese KM, Sweeney FJ, Taylor TJ, Trebino CE, Abramov YA, Laird ER, Volberg WA, Zhou J, Bach J, Lombardo F..  (2006)  Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development.,  16  (16): [PMID:16759861] [10.1016/j.bmcl.2006.05.056]

Source

Source(1):

• Scientific Literature